Ilika plc

investor presentation throughout this recorded meeting and teddies will be in listen only mode questions are encouraged can be submitted at any time using the q a tab situated on the right hand corner of screen just simply type in your questions at any time and press send the company may not be in a position to answer every question it received during today's meeting however the company can review all questions submitted today and we'll publish any responses on the investor meet company platform Before we begin, we'd like to submit the following poll, and I'm sure the company would be most grateful for your participation. I'd now like to hand over to CEO Graham Purdy. Good afternoon.

Thank you, Mark. Good afternoon to everybody who's taken the time to dial into this presentation. We really appreciate it, and we look forward to talking you through this update of Illica's progress. These are, in fact, our half-year results. These are published at the halfway point through the current financial year. The halfway point was at the end of October 2023, and these are an update of the period, the six-month period, up to that end of month. so uh first of all um let me say that we intend to cover uh the full illica story uh apologies to those of you who have been following the company for some time now um we will uh because there are some new attendees who aren't quite so familiar give the overview of the whole um story And we'll be covering all of the bases and also giving a bit more insights into some of the specific progress that's been made in more recent months. So for those of you who are new, there are two product lines that ILICA focuses on. We specialize in the development of solid state batteries. So that's all that the company does. But on the one hand, we have our Steriax miniature cells. that are primarily used to power miniature medical devices and industrial wireless sensors, sometimes referred to as industrial IoT. And then, on the other hand, we have our Goliath large format cells for the automotive industry and also for some cordless consumer appliances. Our EV batteries use an oxide electrolyte and a silicon anode, and I'll go into the competitive landscape and some of the materials choices in a bit more detail as we progress with the presentation. So we've got Jason and myself presenting today. Jason, please say hello. Good afternoon, everybody. Welcome along. Jason's now been with us for a year. He joined as CFO in January of 2023. And if you want more detail on Jason and myself or the non-executive directors who are pictured here, please go to our website. All of their profiles are visible for you to peruse at your leisure. So first of all, a few words on the ILICA business model. I'm going to let Jason talk you through this.

Thank you Graham and for those that are unfamiliar with the Illica story we operate an asset light licensing model which is different from some of the other battery development companies you may have read about in the press or be following in the US as an example. So a number of those other companies are attempting to both develop the technology and then scale all the way to Gigafactory themselves which is a fairly substantial investment into the billions of pounds or dollars, depending on where they're based, and a really substantial investment from their shareholders to be able to bring that to market. And that also requires them to be masters of both the research development and the manufacturing processes required to get that gigafactory up and running at an efficient manner. At Illica, we've decided to take a slightly different approach. We recognise where our core skills lie, and that is in the research and development front. So we are going to pursue a model where we have the incumbent scientists to develop the technology. we will demonstrate that on production intent equipment so to demonstrate that it can be manufactured on pieces of equipment that you would find in a gigafactory albeit larger versions of those machines but at that point we would seek to enter into licensing agreements with partners so that we could then piggyback off their expertise from a manufacturing point of view, and also the fact that they are already part of that supply chain for either the medtech or the automotive environment, making that transition from R&D into mass market production that much easier. And that's very much the model that we've deployed with Certec over the last year.